Phase 3
N=394
Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs
HIV Infections
Bottom Line
View on ClinicalTrials.gov: NCT04140266 ↗Enrolled (actual)
394
Serious AEs
1.5%
Results posted
Aug 2023
Primary outcome: Primary: Number of Mother Participants With Serious Adverse Events (SAEs) Including Maternal Deaths in Both Study Arms — 2; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Dapivirine (DPV) Vaginal Ring (VR)-004 (Drug); Truvada Tablet (Drug)
- Age
- Pediatric, Adult, Older Adult · 0+ yrs
- Sex
- All
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Primary completion
- Nov 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Mother Participants With Serious Adverse Events (SAEs) Including Maternal Deaths in Both Study Arms |
2; 0 | — |
| PRIMARY Number of Mother Participants With Grade 3 or Higher Adverse Events (AEs) in Both Study Arms |
3; 2 | — |
| PRIMARY Number of Infant Participants With SAEs Including Infant Deaths in Both Study Arms |
4; 0 | — |
| PRIMARY Number of Infant Participants With Grade 3 or Higher AEs in Both Study Arms |
10; 1 | — |
| PRIMARY Number and Proportion of Mothers With Detectable Plasma Dapivirine (DPV) Concentrations |
139; 136; 139; 138; 136; 48 | — |
| PRIMARY Number and Proportion of Mothers With Detectable Emtricitabine Triphosphate (FTC-TP) Concentrations |
45; 46; 38; 34; 38; 1 | — |
| PRIMARY Number and Proportion of Mothers With Detectable Tenofovir Diphosphate (TFV-DP) Concentrations |
47; 48; 45; 44; 47; 45 | — |
| PRIMARY Number and Proportion of Mothers With Detectable Breastmilk DPV Concentrations |
137; 137; 138; 138; 135; 94 | — |
| PRIMARY Number and Proportion of Mothers With Detectable Breastmilk FTC Concentrations |
47; 45; 44; 39; 40; 1 | — |
| PRIMARY Number and Proportion of Mothers With Detectable Breastmilk TFV Concentrations |
47; 44; 42; 38; 38; 3 | — |
| PRIMARY Number and Proportion of Infants With Detectable Plasma DPV Concentrations |
21; 20; 14; 7; 0 | — |
| PRIMARY Number and Proportion of Infants With Detectable FTC-TP Concentrations |
4; 2; 2; 1; 0 | — |
| PRIMARY Number and Proportion of Infants With Detectable TFV-DP Concentrations |
0; 0; 0; 0; 0 | — |
| PRIMARY Geometric Mean of Maternal DPV Concentrations From Plasma by Visit |
327.9; 314.9; 275.4; 263.8; 260.4; 16.7 | — |
| PRIMARY Geometric Mean of Maternal FTC-TP Concentrations by Visit |
0.3; 0.3; 0.3; 0.2; 0.2; 0.1 | — |
| PRIMARY Geometric Mean of Maternal TFV-DP Concentrations by Visit |
254.6; 424.2; 524.7; 551.9; 591.5; 330.8 | — |
| PRIMARY Geometric Mean of Maternal DPV Concentrations From Breastmilk by Visit |
529.4; 492.0; 457.0; 418.9; 402.8; 20.0 | — |
| PRIMARY Geometric Mean of Maternal FTC Concentrations From Breastmilk by Visit |
552.6; 447.6; 319.9; 313.0; 296.6; 2.8 | — |
| PRIMARY Geometric Mean of Maternal TFV Concentrations From Breastmilk by Visit |
5.6; 4.3; 3.3; 3.2; 2.7; 0.6 | — |
| PRIMARY Geometric Mean of Infant DPV Concentrations From Plasma by Visit |
11.7; 11.5; 11.0; 10.5; 10 | — |
| PRIMARY Geometric Mean of Infant FTC-TP Concentration by Visit |
0.1; 0.1; 0.1; 0.1; 0.1 | — |
| PRIMARY Geometric Mean of Infant TFV-DP Concentrations by Visit |
15.6; 15.6; 15.6; 15.6; 15.6 | — |
| SECONDARY The Number of Mothers Non-adherent to Study Product for Each Month of Product Use by Study Product |
14; 2; 28; 0; 29; 0 | — |
| SECONDARY Residual Drug Levels in Returned VRs |
22.1; 22.4; 22.1 | — |
| SECONDARY Participant Willingness to Use Their Assigned Study Products During Breastfeeding in the Future (Y/N) |
142; 48 | — |
| SECONDARY Proportion of Participants Who Find Their Study Product to be at Least as Acceptable as Other HIV Prevention Methods |
141; 46 | — |
Summary
The purpose of this study is to evaluate the safety and drug detection of the dapivirine vaginal ring and oral Truvada in breastfeeding mother-infant pairs.
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria - Mother
Participant mothers must meet all the following criteria to be eligible for inclusion in the study:
- Age 18 years or older at Screening, as verified per site Standard Operating Procedures (SOPs).
- At Enrollment, between 6 to 12 weeks postpartum (verified by birth records and/or similar supportive documentation and defined as between 42 - 84 days after delivery, inclusive).
- By participant report at Screening and Enrollment, currently exclusively breastfeeding one infant and willing and able to continue exclusively breastfeeding that infant for the duration of their participation in the study.
- Note: Exclusive breastfeeding will be defined as infant nutrition solely from breast milk, as determined by 7-day recall breastfeeding history. For the purposes of MTN-043, "breastfeeding" refers to all human milk feeding situations when an infant is fed with participant's own human milk whether the milk is received directly from the breast or as expressed milk.
- Consistently using an effective method of contraception per participant report at Enrollment, and intending to continue use of an effective method for the duration of study participation. Effective methods include contraceptive implants, intrauterine device, injectable progestin, oral contraceptive pills, and surgical sterilization.
- Able and willing to comply with all study requirements and complete all study procedures.
- Able and willing to provide the following:
- Written informed consent to be screened for and to take part in the study.
- Written informed consent for the breastfed infant to be screened for and take part in the study.
- Intention to stay within study catchment area for study duration and willingness to give adequate locator information, as defined in site SOPs.
- At Screening and Enrollment, HIV-uninfected based on HIV testing performed by study staff (per algorithm in the study protocol).
- At Screening and Enrollment, willing to be randomized at time of enrollment to either of the study products, and to continue study product use for at least 12 weeks.
Inclusion Criteria - Infant
Each mother eligible for MTN-043 will be asked to provide written informed consent for herself and her infant to participate in the study if the infant meets the following criteria:
- At Screening and Enrollment, infant is exclusively breastfed.
- Note: Exclusive breastfeeding will be defined as infant nutrition solely from breast milk, as determined by 7-day recall breastfeeding history. For the purposes of MTN-043, "breastfeeding" refers to all human milk feeding situations when an infant is fed with participant's own human milk whether the milk is received directly from the breast or as expressed milk.
- At Screening and Enrollment, the infant is generally healthy, according to the judgment of the investigator of record (IoR)/designee.
- At Enrollment, the infant is between the ages of 6 and 12 weeks postpartum (verified by birth records and/or similar supportive documentation with age defined as between 42 - 84 days after delivery, inclusive).
Exclusion Criteria
Exclusion Criteria - Mother
Mothers who meet any of the following criteria will be excluded from the study:
- At Screening or Enrollment, breastfeeding infant ineligible for enrollment in the study.
- At Screening or Enrollment, participant reports any of the following:
- Known adverse reaction to any of the study products (ever).
- Known adverse reaction to latex and polyurethane (ever).
- Post-exposure prophylaxis (PEP) for HIV exposure within 6 months prior to Enrollment.
- Use of vaginal medications(s) or other vaginal products within five days prior to Enrollment.
- Non-therapeutic injection drug use in the 12 months prior to Enrollment.
- History of exposure to any investigational drug(s) during pregnancy, including participation in MTN-042.
- At Screening or Enrollment, has a positive HIV test.
- At Screening or Enrollment, Grade 2 or higher br
Data sourced from ClinicalTrials.gov (NCT04140266). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.